



CUPID LIMITED

Manufacturer & Exporter of Male Condoms, Female Condoms,
Water based Lubricants & In Vitro Diagnostics (IVD) Kits

We Help The World Play Safe

Date: - 10/04/2024

To,

Department of Corporate Services,

BSE LIMITED,

Phiroze Jeejeebhoy Towers,

Dalal Street,

Mumbai – 400 001

SCRIP CODE: 530843

The National Stock Exchange of India Ltd.

Exchange Plaza, 5th Floor, Bandra-Kurla

Complex, Bandra (East),

Mumbai - 400051

• Fax No. – 6641 8125 / 26

SCRIP CODE: CUPID

**SUBJECT: - NEWSPAPER CLIPPINGS OF AUDITED FINANCIAL RESULTS FOR
QUARTER AND FINANCIAL YEAR ENDED ON 31st MARCH, 2024**

Dear Sir / Madam,

With reference to captioned subject enclosed herewith the Newspaper Clippings of Audited Financial Results for quarter and financial year ended on 31st March, 2024 published by the company in newspapers named as "Business Standard" (English Language) and "Maharashtra Times" (Marathi Language) dated 10th April, 2024.

Further, in Maharashtra Times, face value of equity share is wrongly mentioned as Rs. 10/- instead of Re. 1/-.

This is for your information.

Please take the same on your records and acknowledge the receipt.

Thanking you.

For Cupid Limited

Saurabh V. Karmase

Company Secretary and Compliance officer



CIN No.: L25193MH1993PLC070846

Factory & Registered Office:



A-68, M.I.D.C. (Malegaon), Sinnar,
Nashik - 422113, Maharashtra, India



+91 2551 230280 / 230772
+91 7722009580



www.cupidlimited.com
info@cupidlimited.com

Name of Newspapers: - Business Standard (English) & Maharashtra Times (Marathi)

Date of Publication: - 10th April, 2024



क्युपिड
लिमिटेड

पुरुष / महिलांचे कंडोम्स, ल्युब्रिकंटस् आणि इन विट्रो डायग्नोस्टिक्स (IVD)
चे उत्पादक व निर्यातदार

A-६८, M.I.D.C. (माळेगाव), सिन्नर, नाशिक - ४२२११३, महाराष्ट्र,

फोन नं. :- +९१ २५५१ २३०२८०/२३०७७२, फॅक्स नं. :- +९१ २५५१ २३०२७९

सीन नं. :- एल२५१९३एमएच१९९३पीएलसी०७०८४६

ई-मेल :- cs@cupidlimited.com वेबसाईट :- www.cupidlimited.com

मार्च ३१, २०२४ ला संपलेल्या तिमाही आणि वर्षाकरीता लेखापरिक्षित वित्तीय निष्कर्षांचा अर्क

(प्रतिभाग मिळकत सोडून ₹ लाखांमध्ये)

अनु क्र.	तपशिल	तिमाही संपला			वर्ष संपले	
		३१/०३/२०२४	३१/१२/२०२३	३१/०३/२०२३	३१/०३/२०२४	३१/०३/२०२३
		(लेखापरिक्षित)	(अलेखापरिक्षित)	(लेखापरिक्षित)	(लेखापरिक्षित)	(लेखापरिक्षित)
१.	प्रचलनातुन एकुण महसुल	६,५८७.७८	४,०७७.९७	४,३४८.७७	१७,८३०.४९	१६,४०९.६९
२.	कर कालावधी पुर्वीसाठी निव्वळ नफा (अपवादात्मक आणि असामान्य बाबीपुर्वी)	३,२२०.६२	१,१७३.४३	१,११९.०१	५,२५८.१८	४,२३१.९०
३.	कर कालावधी पुर्वीसाठी निव्वळ नफा (अपवादात्मक आणि असामान्य बाबीनंतर)	३,२२०.६२	१,१७३.४३	१,११९.०१	५,२५८.१८	४,२३१.९०
४.	कर नंतरच्या कालावधीसाठी निव्वळ नफा	२,३७१.७१	८८६.३५	८३३.५५	३,९८५.४८	३,१५८.२८
५.	कालावधीसाठी एकुण व्यापक उत्पन्न	२,३५६.९८	८८६.३५	८२७.८९	३,९३७.५३	३,१४५.९४
अ)	भरणा केलेले समभाग भांडवल	१,३४१.७७	१,३३३.८०	१,३३३.८०	१,३४१.७७	१,३३३.८०
ब)	ताळेबंदानुसार पुनर्मुल्यांकन राखीव वगळता राखीव ठेव.	—	—	—	१९,१५६.२७	१५,३७८.५४
क)	प्रतिभाग मिळकत (दर्शनी मुल्य ₹ १०/- प्रत्येकी)					
	i) बेसीक (₹ मध्ये)	१.७८	०.६६	०.६२	२.९८	२.३७
	ii) डायल्युटेड (₹ मध्ये)	१.७७	०.६५	०.६१	२.९७	२.३६
			पुनर्स्थित केले	पुनर्स्थित केले		पुनर्स्थित केले

सूचना :- उपरोक्त वित्तीय निष्कर्षांचे तपशिलवार स्वरूप सेबी (लिस्टिंग ऑब्लिगेशन्स अँड डिस्क्लोजर रिक्वायर्मेंट्स) रेग्युलेशन्स, २०१५च्या रेग्युलेशन ३३ अंतर्गत स्टॉक एक्सचेंजेस सोबत फाईल केले आहे. सदर वित्तीय निष्कर्षांचे संपूर्ण स्वरूप स्टॉक एक्सचेंजेसच्या वेबसाईट www.bseindia.com आणि www.nseindia.com तसेच कंपनीची वेबसाईट www.cupidlimited.com वर उपलब्ध आहेत.

ठिकाण :- कोलकाता

तारीख :- ८ एप्रिल, २०२४

क्युपिड लिमिटेड करीता

स्वाक्षरी/-

आदित्य कुमार हलवासिया

व्यवस्थापकीय संचालक

Domestic business, easing price pressure to boost pharma margins

SOHINI DAS
Mumbai, 9 April

Indian pharma companies are expected to post 14-15 per cent year-on-year (Y-o-Y) revenue growth in the fourth quarter of 2023-2024, analysts forecast, attributing this surge to robust domestic business and benefits from benign price erosion in the US.

The earnings before interest, taxes, depreciation, and amortization (Ebitda) growth is estimated to come in around 22-30 per cent Y-o-Y by several brokerages.

Meanwhile, as the fourth quarter is seasonally better for healthcare and diagnostic companies, revenues for hospitals and diagnostic companies overall is expected to grow by 13-15 per cent Y-o-Y, while the Ebitda is expected to grow by 25 per cent or so.



IN GOOD HEALTH

Company	Net sales (in ₹ crore)	Change (%)	Ebitda (in ₹ crore)	Change (%)
Sun Pharma Industries	12,249	0.8	3,188	-4.9
Cipla	6,249	-4.0	1,347	-22.9
Apollo Hospitals Enterprise	4,926	1.5	665	8.3
Fortis Healthcare	1,814	8.0	333	17.4
Dr Lal PathLabs	552	2.3	143	23.3

*E-estimates; year-on-year. Source: Bloomberg. Compiled by BS Research Bureau

Nuvama Institutional Equities noted that generic Revimid (used to treat multiple myeloma) will boost players like Natco, Zydus Lifesciences, Sun Pharmaceutical Industries, Dr Reddy's Laboratories (DRL), Aurobindo etc.

Secondly, the analysts felt that benign price erosion in the US market will benefit generic players like Aurobindo. At the same time, domestic

business is expected to grow by 11 per cent Y-o-Y during the quarter, therefore, companies that have a strong India market presence like Torrent Pharma, Sun Pharma would tend to benefit from their chronic portfolios and addition of sales force.

The acute therapy or anti-infectives growth is expected



RESULT PREVIEW

to remain flat and that can affect Alkem which is an acute-therapy focused company in the domestic market. Overall, lower active pharmaceutical prices will improve gross margins Y-o-Y, Nuvama said.

Prabhudas Lilladher analysts say, "We expect pharmaceuticals companies under our coverage to report another

strong quarter with Ebitda growth of 22 per cent Y-o-Y (down 3 per cent Quarter on Quarter) mainly aided by new launches (generic Revimid, generic Spiriva, etc) in US market; steady domestic business and higher margins."

Analysts also expect the quarter to continue seeing easing of cost pressures which will thereby aid margins Y-o-Y. The companies are likely to witness steady base business in the US given a stable generic pricing environment coupled with new launches. On domestic formulation business, given seasonal weakness, acute and trade generic business may remain soft while chronic business may see steady growth.

Prabhudas Lilladher analysts expect Sun Pharma to report Ebitda growth of 9 per cent Y-o-Y led by continued momentum in the specialty portfolio.

More on business-standard.com

Paytm PB MD & CEO Chawla steps down

ARYAMAN GUPTA
New Delhi, 9 April



According to the firm, Surinder Chawla resigned citing personal reasons and to explore better career prospects

Managing director (MD) and Chief Executive Officer (CEO) of the beleaguered Paytm Payments Bank, Surinder Chawla, has resigned "on account of personal reasons", the company said in a regulatory filing on Tuesday.

The company said the resignation would be effective from June 26 but did not name any potential successor to Chawla, who had been appointed MD and CEO of the company in January 2023 after it received a nod from the Reserve Bank of India (RBI).

"...Surinder Chawla, Managing Director and CEO of the Paytm Payments Bank Ltd (PPBL) has tendered his resignation on April 8, 2024, on account of personal reasons and to explore better

career prospects. He will be relieved from PPBL w.e.f. close of business hours on June 26, 2024, unless changed by mutual consent," the company said.

Before joining PPBL, Chawla was working with RBL Bank, where he served as Head - Branch Banking.

His resignation comes at a time when PPBL has been facing regulatory scrutiny. The RBI, in February, issued directives restricting credit and debit transactions for the bank's customers starting March 15 due to lapses in due diligence.

Last month, Paytm founder Vijay Shekhar Sharma also stepped down from his role as non-executive chairman of PPBL, leading to its board being reconstituted.

"As informed earlier, nearly all agreements between the company and PPBL have been terminated as per our disclosure on March 1, 2024, and the board of PPBL has been reconstituted with five independent directors including an Independent Chairperson, and no nominations from the company, as per our disclosure on February 26, 2024," the company said.

Invesco marks up Swiggy valuation to \$12.7 bn

ARYAMAN GUPTA
New Delhi, 9 April

US-based fund manager Invesco has marked up the valuation of initial public offering (IPO)-bound food delivery major Swiggy for the third consecutive time to \$12.7 billion, a 19 per cent increase from what the company was valued at during its last fundraising, according to regulatory filings.

The Bengaluru-based startup raised a massive \$700 million funding round led by Invesco in January 2022, which made Swiggy a decacorn, valued at \$10.7 billion.

After facing a spate of valuation cuts early last year due to high cash burn and poor margins, Swiggy has been on

a path of financial recovery as it gears up for a \$1 billion (₹8,300 crore) IPO likely later this year. As such, its investors have been consecutively marking up Swiggy's valuation over the last year.

Invesco, in October last year, marked up Swiggy's valuation to \$7.85 billion. It subsequently marked up this figure to \$8.3 billion in January this year, before now valuing the company at \$12.7 billion.

Besides Invesco, US-headquartered asset management firm Baron Capital also marked up Swiggy's valuation to \$8.54 billion in August last year. It again

marked up Swiggy's valuation to \$12.1 billion last month.

Swiggy did not comment on the development.

The markups have brought Swiggy's valuation closer to that of its rival, Zomato, whose share price has surged to a record high of ₹193.7

The recent mark-ups have brought Swiggy's valuation closer to that of its rival Zomato. The BSE-listed company has witnessed a surge in its share price, reaching a record high of ₹193.7 per share as of April 9. This strong performance, driven primarily by its quick-commerce segment, has propelled Zomato's market capitalisation to over \$20 billion.

Investors usually take into account the valuations in the public market

when assessing private market companies, and Swiggy is no different.

Since the beginning of 2023, Swiggy has undergone retrenchments by way of layoffs and shutting many of its business verticals. The firm also introduced a ₹2 platform fee for all its users, after which it hiked this fee to ₹10. This led to its food delivery business turning profitable in the March quarter of FY23 (Q4 FY23) after considering corporate costs and excluding employee stock options (ESOP).

According to filings from Swiggy's largest investor Prosus, Swiggy's core food delivery business grew 17 per cent to deliver a gross merchandise value (GMV) of \$1.43 billion in the first half of FY24.

Pallia: Energised by possibilities in era of tech progress

PRESS TRUST OF INDIA
New Delhi, 9 April

Wipro's new Chief Executive Officer Srinivas Pallia (pictured) said he was energised by possibilities before the company and the industry in a new era fuelled by rapid technological progress.



moulding and shaping him into the leader he is today, according to sources.

"As we enter a new era fuelled by rapid technological progress, I am energised by the possibilities ahead for our company and our industry. I look forward to working with all our 240,000 Wiproites around the globe and taking this iconic company to its next phase of growth," he said.

Pallia said over the past four years, he worked closely with Delaporte and the entire leadership team on an ambitious transformation journey.

Wipro's top boss — who took over the baton from Thierry Delaporte at the \$11 billion IT services firm on Saturday — penned a post on LinkedIn to say he looked forward to working with 240,000 "wiproites" and taking the "iconic" firm to the next phase of growth.

"There's a lot of work still to be done ahead of us," Pallia wrote in the recent post. Pallia also reached out to employees through an email where he talked about his journey of continuous discovery, growth, and learning at Wipro

Ramdev, Balkrishna file 'unconditional' apology in Patanjali ad case

Final SC verdict expected today

BHAVINI MISHRA
New Delhi, 9 April

Baba Ramdev and Patanjali Ayurved Managing Director Acharya Balkrishna on Tuesday submitted a fresh affidavit in the Supreme Court, seeking an 'unconditional and unqualified apology' in connection with the misleading advertisements claiming cure for diseases and defaming allopathy.

Balkrishna had placed his apology before the court, Ramdev's affidavit was not on record. On this, the court had said it was clear that the matter had to be taken to its "logical conclusion".

The bench of justices Hima Kohli and Ahsanuddin Amanullah was furious and had asked the respondents as to why contempt proceedings shouldn't be initiated against them for "flouting its directions".

Ramdev and Balkrishna had on November 21, 2023 assured the court that they would not make any "casual statements claiming medicinal efficacy or against any system of medicine". But, a day later, on November 22, Ramdev held a press conference saying remedies for blood pressure were "lies spread by allopathy".

NAVI AMC LIMITED
Registered Office: "Vaishnavi Tech Square, 7th Floor, Iballur Village, Begur, Hobli, Bengaluru, Karnataka 560102"
Tel: 080 45113400; Toll free no. 1800 103 8999
Website: <https://navi.com/mutual-fund> Email: mf@navi.com
CIN: U65990KA2009PLC165296

Notice No. 01 of 2024-25

NOTICE is hereby given to all unit holders of Navi Mutual Fund ("Mutual Fund") that in accordance with Regulation 59A of Securities and Exchange Board of India (Mutual Funds) Regulations, 1996 read with paragraph 5.1 of SEBI Master Circular dated May 19, 2023, the half yearly portfolio of the schemes of the Fund as on March 31, 2024 has been hosted on the website of Navi AMC Limited (the AMC) viz. <https://navi.com/mutual-fund/downloads/portfolio> and on the website of AMFI viz. www.amfiindia.com.

Investors can request for physical or electronic copy of half yearly portfolios of the schemes of the Fund via following means:

- Telephone: 1800-103-8999
- Email: mf@navi.com
- Letter: Submit at the registered office of the Company

For Navi AMC Limited
(Investment Manager to Navi Mutual Fund)

Sd/-
Authorized Signatory

MUTUAL FUND INVESTMENTS ARE SUBJECT TO MARKET RISKS, READ ALL SCHEME RELATED DOCUMENTS CAREFULLY

Manufacturer & Exporter of Male Condoms, Female Condoms, Water Based Lubricant and In Vitro Diagnostics (IVD)

A-68, M.I.D.C. (Malegaon), Sinnar, Nashik-422 113, Maharashtra, India,
Tel No.: +91 2551 230280 / 230772, Fax: +91 2551 230279 CIN No.: - L25193MH1993PLC070846
E-mail: cs@cupidlimited.com Website: www.cupidlimited.com

EXTRACT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31st MARCH, 2024						
(Rs. in Lacs except EPS)						
SR. No.	PARTICULARS	QUARTER ENDED			YEAR ENDED	
		31.03.2024 (Audited)	31.12.2023 (Unaudited)	31.03.2023 (Audited)	31.03.2024 (Audited)	31.03.2023 (Audited)
1	Total income	6,587.78	4,077.97	4,348.77	17,830.49	16,409.69
2	Net Profit for the period (before Tax, Exceptional and Extraordinary items)	3,220.62	1,173.43	1,119.01	5,258.18	4,231.90
3	Net Profit for the period before tax (after Exceptional and Extraordinary items)	3,220.62	1,173.43	1,119.01	5,258.18	4,231.90
4	Net Profit for the period after tax	2,371.71	886.35	833.55	3,985.48	3,158.28
5	Total Comprehensive Income for the period	2,356.98	886.35	827.89	3,937.53	3,145.94
A	Paid up Equity Share Capital	1,341.77	1,333.80	1,333.80	1,341.77	1,333.80
B	Reserves excluding Revaluation Reserve as per balance sheet	—	—	—	19,156.27	15,378.54
C	Earnings Per Share (Face Value of Rs. 1/- each)					
	i) Basic (Amount in INR)	1.78	0.66	0.62	2.98	2.37
	ii) Diluted (Amount in INR)	1.77	0.65	0.61	2.97	2.36
			Restated	Restated		Restated

Note: The above is an extract of the detailed format of Quarterly and Annual Financial Results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available on company's website at www.cupidlimited.com and on the websites of the Stock Exchanges at www.bseindia.com and www.nseindia.com.

For CUPID LIMITED
Sd/-
Aditya Kumar Halwasiya
Managing Director

Place: Kolkata
Date: 8th April, 2024

MAITHON POWER LIMITED
(Contracts Department)
Maithon Power Ltd, Village: Dambhui, PO Barabindia, District: Jharkhand, State: Jharkhand PIN-828205
NOTICE INVITING EXPRESSION OF INTEREST
The Maithon Power Limited invites expression of interest from eligible vendors for the following package:
Services for Inspection and Overhauling of Boiler Fans & RAPH during Unit#2 AOH in FY25 AT 25 x 2 MW THERMAL POWER PLANT.
For details of pre-qualification requirements, bid security, purchasing of tender document etc., please visit Tender section of our website (URL: <https://www.tatapower.com/tender/tenderlist.aspx>). Eligible vendors willing to participate may submit their expression of interest along with the tender fee for issue of bid document latest by 22nd April 2024.

APPOINTMENTS

BOB Capital Markets Limited
(wholly owned subsidiary of Bank of Baroda)
Registered and Corporate Office:
1704, B Wing, 17th Floor, Parinex Crescencio, Plot no. 38/39, G Block, Bandra East, Mumbai 400051
Tel: +91 22 6138 9300

RECRUITMENT/ JOB OPENINGS

BOB Capital Markets invites applications for recruitment for the following positions:

Sl. No.	Department	Position	Location	No. of Posts
1	Investment Banking - Equity	VP/ SVP: Origination & Business Development in ECM & Advisory (Min. Experience - 10/12 Years)	Mumbai	2
2	Compliance (Retail & Institutional Broking)	Sr Manager: SEBI & Stock Exchange compliances, Inspections, Audits, Regulatory filings and related roles. (Min. Experience 10 Years)	Mumbai	1
3	Risk	Chief Risk Officer - Risk Management for Retail/ Institutional Broking (Min. Experience 15 Years)	Mumbai	1
4	Retail Broking	Manager: Digital Product: Managing Retail Broking products and platform (Min. Experience 5 Years)	Mumbai	1
5	Institution Sales	Sr. Manager: Institutional Equities cash & Derivative Sales Trader (Min. Experience 10 Years) AVP: Institution Equity cash & Derivative Sales Trader (Min. Experience 15 Years)	Mumbai	1
6	Research	Analyst: NBFC, Pharma (Min. Experience -5 Years)	Mumbai	2

Eligibility criteria and related information is available in the careers section of the Company's website www.bobcaps.in. Please email your CV with salary expectations along with a recent photograph to careers@bobcaps.in on or before 15th April 2024. (by 23:59 hours).

Applicants with requisite qualifications should only apply
Remuneration - Remuneration will be offered based on candidate's qualifications, work experience, overall suitability, last drawn salary of the candidate and market benchmark for the position as mentioned in the detailed Job Description on company's website.
Addendum/ modifications if any, including change in Last Date of application, shall be notified only on the Company's website; interested applicants are requested to refer to the same before submission of the application.
Date : 09.04.2024
Place : Mumbai
Sd/-
Head (HR & Admin.)

